Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- capecitabine
- cedazuridine / decitabine
Interactions between your drugs
capecitabine cedazuridine
Applies to: capecitabine, cedazuridine / decitabine
GENERALLY AVOID: Coadministration with cedazuridine may increase the systemic exposure of drugs that are metabolized by the cytidine deaminase (CDA) enzyme. The mechanism involves inhibition of CDA by cedazuridine. Increased toxicity or altered efficacy of CDA substrates may result.
MANAGEMENT: Coadministration of cedazuridine with drugs that are metabolized by CDA should generally be avoided.
References (5)
- (2001) "Product Information. Xeloda (capecitabine)." Roche Laboratories
- Garcia-Manero G, Stoltz M, Ward M, et al. (2008) "A pilot pharmacokinetic study of oral azacitidine." Leukemia, 22, p. 1680-4
- Bhatla D, Gerbing RB, Alonzo TA, et al. (2009) "Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia." Br J Haematol, 144, p. 388-94
- Gilbert JA, Salavaggione OE, Ji Y, et al. (2006) "Gemcitabine pharmacogenomics: dytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics." Clin Cancer Res, 12, p. 1794-803
- (2020) "Product Information. Inqovi (cedazuridine-decitabine)." Taiho Oncology, Inc.
Drug and food interactions
cedazuridine food
Applies to: cedazuridine / decitabine
ADJUST DOSING INTERVAL: There are no data regarding the concurrent administration of oral cedazuridine-decitabine with food.
MANAGEMENT: The manufacturer recommends that patients avoid eating for 2 hours before and 2 hours after administration of oral cedazuridine-decitabine.
References (1)
- (2020) "Product Information. Inqovi (cedazuridine-decitabine)." Taiho Oncology, Inc.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Arimidex
Arimidex is used to treat breast cancer in postmenopausal women. Learn about side effects ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.